Clinical Trial Detail

NCT ID NCT01923168
Title Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Buparlisib + Letrozole

Letrozole

Alpelisib + Letrozole

Age Groups: adult

Additional content available in CKB BOOST